Cargando…

Downregulation of dual‐specificity tyrosine‐regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin‐dependent kinase 14 expression in breast cancer

Tumor progression is the main cause of death in patients with breast cancer. Accumulating evidence suggests that dual‐specificity tyrosine‐regulated kinase 2 (DYRK2) functions as a tumor suppressor by regulating cell survival, differentiation, proliferation and apoptosis. However, little is known ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Imawari, Yoshimi, Mimoto, Rei, Hirooka, Shinichi, Morikawa, Toshiaki, Takeyama, Hiroshi, Yoshida, Kiyotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797831/
https://www.ncbi.nlm.nih.gov/pubmed/29193658
http://dx.doi.org/10.1111/cas.13459
_version_ 1783297760841170944
author Imawari, Yoshimi
Mimoto, Rei
Hirooka, Shinichi
Morikawa, Toshiaki
Takeyama, Hiroshi
Yoshida, Kiyotsugu
author_facet Imawari, Yoshimi
Mimoto, Rei
Hirooka, Shinichi
Morikawa, Toshiaki
Takeyama, Hiroshi
Yoshida, Kiyotsugu
author_sort Imawari, Yoshimi
collection PubMed
description Tumor progression is the main cause of death in patients with breast cancer. Accumulating evidence suggests that dual‐specificity tyrosine‐regulated kinase 2 (DYRK2) functions as a tumor suppressor by regulating cell survival, differentiation, proliferation and apoptosis. However, little is known about the mechanisms of transcriptional regulation by DYRK2 in cancer progression, particularly with respect to cancer proliferation and invasion. Here, using a comprehensive expression profiling approach, we show that cyclin‐dependent kinase 14 (CDK14) is a target of DYRK2. We found that reduced DYRK2 expression increases CDK14 expression, which promotes cancer cell proliferation and invasion in vitro, in addition to tumorigenicity in vivo. CDK14 and DYRK2 expression inversely correlated in human breast cancer tissues. We further identified androgen receptor (AR) as a candidate of DYRK2‐dependent transcription factors regulating CDK14. Taken together, our findings suggest a mechanism by which DYRK2 controls CDK14 expression to regulate tumor cell proliferation and invasion in breast cancer. Targeting of this pathway may be a promising therapeutic strategy for treating breast cancer.
format Online
Article
Text
id pubmed-5797831
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57978312018-02-14 Downregulation of dual‐specificity tyrosine‐regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin‐dependent kinase 14 expression in breast cancer Imawari, Yoshimi Mimoto, Rei Hirooka, Shinichi Morikawa, Toshiaki Takeyama, Hiroshi Yoshida, Kiyotsugu Cancer Sci Original Articles Tumor progression is the main cause of death in patients with breast cancer. Accumulating evidence suggests that dual‐specificity tyrosine‐regulated kinase 2 (DYRK2) functions as a tumor suppressor by regulating cell survival, differentiation, proliferation and apoptosis. However, little is known about the mechanisms of transcriptional regulation by DYRK2 in cancer progression, particularly with respect to cancer proliferation and invasion. Here, using a comprehensive expression profiling approach, we show that cyclin‐dependent kinase 14 (CDK14) is a target of DYRK2. We found that reduced DYRK2 expression increases CDK14 expression, which promotes cancer cell proliferation and invasion in vitro, in addition to tumorigenicity in vivo. CDK14 and DYRK2 expression inversely correlated in human breast cancer tissues. We further identified androgen receptor (AR) as a candidate of DYRK2‐dependent transcription factors regulating CDK14. Taken together, our findings suggest a mechanism by which DYRK2 controls CDK14 expression to regulate tumor cell proliferation and invasion in breast cancer. Targeting of this pathway may be a promising therapeutic strategy for treating breast cancer. John Wiley and Sons Inc. 2018-01-13 2018-02 /pmc/articles/PMC5797831/ /pubmed/29193658 http://dx.doi.org/10.1111/cas.13459 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Imawari, Yoshimi
Mimoto, Rei
Hirooka, Shinichi
Morikawa, Toshiaki
Takeyama, Hiroshi
Yoshida, Kiyotsugu
Downregulation of dual‐specificity tyrosine‐regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin‐dependent kinase 14 expression in breast cancer
title Downregulation of dual‐specificity tyrosine‐regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin‐dependent kinase 14 expression in breast cancer
title_full Downregulation of dual‐specificity tyrosine‐regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin‐dependent kinase 14 expression in breast cancer
title_fullStr Downregulation of dual‐specificity tyrosine‐regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin‐dependent kinase 14 expression in breast cancer
title_full_unstemmed Downregulation of dual‐specificity tyrosine‐regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin‐dependent kinase 14 expression in breast cancer
title_short Downregulation of dual‐specificity tyrosine‐regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin‐dependent kinase 14 expression in breast cancer
title_sort downregulation of dual‐specificity tyrosine‐regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin‐dependent kinase 14 expression in breast cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797831/
https://www.ncbi.nlm.nih.gov/pubmed/29193658
http://dx.doi.org/10.1111/cas.13459
work_keys_str_mv AT imawariyoshimi downregulationofdualspecificitytyrosineregulatedkinase2promotestumorcellproliferationandinvasionbyenhancingcyclindependentkinase14expressioninbreastcancer
AT mimotorei downregulationofdualspecificitytyrosineregulatedkinase2promotestumorcellproliferationandinvasionbyenhancingcyclindependentkinase14expressioninbreastcancer
AT hirookashinichi downregulationofdualspecificitytyrosineregulatedkinase2promotestumorcellproliferationandinvasionbyenhancingcyclindependentkinase14expressioninbreastcancer
AT morikawatoshiaki downregulationofdualspecificitytyrosineregulatedkinase2promotestumorcellproliferationandinvasionbyenhancingcyclindependentkinase14expressioninbreastcancer
AT takeyamahiroshi downregulationofdualspecificitytyrosineregulatedkinase2promotestumorcellproliferationandinvasionbyenhancingcyclindependentkinase14expressioninbreastcancer
AT yoshidakiyotsugu downregulationofdualspecificitytyrosineregulatedkinase2promotestumorcellproliferationandinvasionbyenhancingcyclindependentkinase14expressioninbreastcancer